Join us in this live and interactive webinar - the final segment in a 4-part series of talks on common and frustrating skin diseases encountered in companion animals.
In this presentation Dr. Pieper will continue the discussion on canine atopic dermatitis with a focus on moderate to severe cases of disease. His discussion will include:
- Characteristics of moderate to severe disease
- Current therapeutic options including JAK inhibitors (Apoquel and Zenrelia) and when they should be implemented into treatment plans
- The role of monoclonal antibodies and how Cytopoint can be used as part of patient management
- The ideal cases for allergen specific immunotherapy and testing options
Approved for 1 hour of CE credit by AAVSB RACE and NY State
You might also like
Dispelling Cancer Treatment Myths And Addressing Quality Of Life Of Affected Dogs And Cats
12/11/2024
Cancer is a word that can evoke a lot of fear and uncertainty, especially when it affects our animal...
Read
More
Supporting The Cancer Patient: Managing Cancer Pain, Nutritional Needs Of Patients, And Supporting The Caregiver Through It All
12/04/2024
Aside from the plan prescribed to treat a pet’s cancer, we have to ensure that we are addressi...
Read
More
Hemangiosarcoma - What We Know And How That's Changing The Paradigm Of Treatment And Prevention
11/13/2024
Hemangiosarcoma is a malignant tumor and, historically, associated with a poor long term prognosis....
Read
More
Treating Cancer - It's Not Just Limited To "chemo" Or "radiation"
11/06/2024
There are different approaches to cancer treatment and, for some types of cancer, the therapy may be...
Read
More
Cancer Diagnostics - What Is Helpful? What Is Hype Or Truly Offers Hope?
10/30/2024
The mention of 'cancer' can evoke a wide range of emotions ranging from fear to concern to confusion...
Read
More
Protein-Losing Enteropathy - Therapeutic Management And The Crucial Role Of Nutrition
09/17/2024
In this second session (of a two part series) Dr. Jablonski continues the discussion on patient mana...
Read
More
